SARS-CoV-2 Antibody Semi-Quantitative Levels Is Important In The Management Of COVID-19 Vaccinations In Immunodeficiency Disorder Patients.

https://doi.org/10.1016/j.jaci.2022.12.083Get rights and content

Section snippets

Rationale

The efficacy and durability of SARS-CoV-2 immunological antibody response in Immunodeficiency Disorder (ID) patients (including Primary Immunodeficiency) can be utilized in their clinical management to avoid COVID-19 infection. We correlated SARS-CoV-2 antibody semi-quantitative test results with ID patients’ COVID-19 vaccinations, their timing, IVIG infusions, and clinical outcomes.

Methods

Retrospective EMR database review of ID patients from January 2021 to August 2022 tested by the semi-quantitative GenScript SARS-CoV-2 Neutralization Antibody Test. Statistical analysis of compiled data included the correlation between antibody titer test results, vaccinations, IVIG therapy, and chart review for COVID-19-related health outcomes.

Results

Antibody testing was performed four weeks after each ID patient was fully vaccinated (n=99); 76% achieved positive antibody titers (low to high levels). Of the 23 initially negative antibody patients, 17 turned positive after 1 booster dose, 2 turned positive after the second booster, and 2 needed the third booster; 2 patients failed to achieve even low titer levels (these 2 patients received Evusheld). Sustained high antibody levels typically persisted from 3 to 6 months. ID patients receiving

Conclusions

Our immunodeficiency disorder patients generally produced a humoral immune response to the COVID-19 vaccine. However, the level of vaccination response and durability varies, therefore periodic monitoring of SARS-CoV-2 antibody semi-quantitative levels is important in the optimal management of ID patients.

References (0)

Cited by (0)

View full text